Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma.
Yi LiJinying LuFurong BaiYanan XiaoYiran GuoZiming DongPublished in: BioMed research international (2018)
Osteosarcoma is the most common primary malignancy of bone in children and the elderly. Recently, more and more researches have demonstrated that Ginsenoside Rg3 (Rg3) is involved in chemotherapy resistance in many cancer, making it a promising Chinese herbal monomer for oncotherapy. In this study, we investigated the efficacy of Rg3 in human osteosarcoma cell lines (MG-63, U-2OS, and SaOS-2). Cell proliferation was measured by CCK8 assay. The migration of cells was examined using the scratch assay method. Quantification of apoptosis was assessed further by flow cytometry. In addition, the expression of apoptosis-related genes (caspase9, caspase3, Bcl2, and Bax) were investigated using RT-PCR. We further investigated the protein level expression of Bcl 2, cleaved-caspase3, and PI3K/AKT/mTOR signaling pathway factors by Western blot assay. Our results revealed that Rg3 inhibited the proliferation and migration of human osteosarcoma cells and induced apoptosis in a concentration- and time-dependent manner. Western blot results showed that Rg3 reduced the protein expression of Bcl2 and PI3K/AKT/mTORbut increased the levels of cleaved-caspase3. Therefore, we hypothesized Rg3 inhibits the proliferation of osteosarcoma cell line and induces their apoptosis by affecting apoptosis-related genes (Bcl2, caspase3) as well as the PI3K/AKT/mTOR signaling pathway. To conclude, Rg3 is a new therapeutic agent against osteosarcoma.
Keyphrases
- induced apoptosis
- signaling pathway
- pi k akt
- cell cycle arrest
- endoplasmic reticulum stress
- oxidative stress
- cell death
- endothelial cells
- epithelial mesenchymal transition
- cell proliferation
- poor prognosis
- flow cytometry
- induced pluripotent stem cells
- high throughput
- south africa
- young adults
- pluripotent stem cells
- binding protein
- cell cycle
- squamous cell carcinoma
- radiation therapy
- bone mineral density
- middle aged